Dr. Plotnikoff has a Ph.D. in Pharmacology, with over 20 years in the pharmaceutical industry, working in Pharmacology, Toxicology, and Clinical Research. Dr. Plotnikoff was a Professor of Pharmacology at the University of Illinois Medical Center in Chicago. Dr. Plotnikoff played a pioneering role in investigations of the immunological effects of MENK. He also successfully managed the project teams that developed the NDAs on Traxene (Valium-like tranquilizer) and Cylert (non-amphetamine psychostimulant).
In basic research he was the first to identify the central nervous system effects of hypothalamic releasing factors (brain hormones), resulting in their clinical development for treatment of depression and Parkinson’s disease. Dr. Plotnikoff co-authored 25 publications with Dr. Andrew Schally covering basic research in the field of depression and Parkinson’s disease. Dr. Plotnikoff held a number of international patents for the use of MENK in HIV/AIDS and cancer. TNI BioTech, Inc. acquired these patents in 2012.
Dr. Eugene Youkilis, has a Ph.D. in Toxicology and is a Diplomate of the American Board of Toxicology and former President and Founder of Clinical Bio-Tox Laboratories, Director of Toxicology and Immunobiology at Baxter International, Laboratory Section Chief and Director at Stroger Hospital (formerly Cook County Hospital) and was a Senior Research Investigator with G. D. Searle and Company. He currently is a Principal Associate with Toxicology Resource Associates. Dr. Youkilis in these capacities provided consulting services to industry, research facilities, and the legal profession in the areas of forensic, clinical, and industrial/occupational toxicology. Dr. Youkilis has over 25 years experience in the pharmaceutical and healthcare industry, working in toxicology, pharmacology and clinical research, and is the author or co-author of over 25 presentations and publications. Dr. Youkilis, from 1983 to present, has worked with Dr. Nicholas Plotnikoff involving therapy with MENK for the treatment of HIV/AIDS and cancer patients.
Noreen Griffin is one of the founders and is the Chief Executive Officer of TNI BioTech, Inc. Ms. Griffin was a vital part of the acquisition of the patents and therapies involving MENK and LDN and was involved with the inventors and patent holders for over 5 years before deciding to join the team that formed TNI BioTech, Inc.
Ms. Griffin has over 25 years of industry experience, having founded and led a number of startup companies. She has played an integral role in raising multiple rounds of private and venture capital funds on behalf of clients. Ms. Griffin has owned and operated a small consulting firm located in Washington, D.C. and Florida. She has served as Chief Financial Officer and Vice President of a number of small public companies over the last 10 years. In addition, Ms. Griffin has significant experience acting as a debtor-in-possession.
Mr. Pearce agreed to accept a position with TNI in late 2011, due to his understanding and involvement with the company. Mr. Pearce is one of the founding principals of pH Pharmaceutical, Inc. (a pharmaceutical company focused on the commercial application and licensing of a patented technology) and its affiliated company, pH Solutions, since its inception in December 2007. Mr. Pearce has over 30 years experience as director and chief operating officer of a New York stock exchange-listed company with more than 5,000 employees worldwide and $500 million revenue per annum. His responsibilities included running large operations that required sourcing products and services, contract negotiation, marketing and advertising, scheduling, warehousing and inventory management and employee oversight.
Mr. Pearce was born in the United Kingdom and was educated at Lord Wandsworth College and London University, where he received his LLB (Bachelor of Law). He immigrated to the United States in 1965 where he immediately began his career in the film industry.
Dr. Fengping Shan has a Ph.D. in Microbiology/Immunology. Dr. Shan is the Professor of Immunology and Vice Director of the Institute of Immunology, China Medical University, Shenyang, China. Dr. Shan was the Senior Scientist for Penta Biotech and Chief Scientist for the Institute of Microbiological Science and Studies at the National Cancer Research Center in Paris, France. Dr. Shan is the author of 50 Publications, 11 patents, and unique inventor for a thrombolytic enzyme from the earthworm. From 2000 he has worked with Dr. Nicholas Plotnikoff involving new therapy with MENK for the treatment of cancer. Patents were filed in 2010 and were approved in 2011.
Professor Dalgleish studied medicine at University College London where he obtained an MBBS and a BSc in Anatomy. He is a Fellow of The Royal College of Physicians of the UK and Australia, Royal College of Pathologists and The Academy of Medical Scientists. He also trained in Internal Medicine and Oncology in Brisbane and Sydney. Following an interest in how viruses caused cancer, he undertook a PhD with Professor Robin Weiss, a FRS at the Institute of Cancer Research and Royal Marsden Hospital before becoming a senior clinical scientist at the MRC Clinical Research Center in Northwick Park. He was appointed to Foundation Chair of Oncology at St. George’s University of London in 1991. His main interests there have been the immunology of cancer and the development of immunotherapies to treat, in particular, melanoma. In 1997, he founded Onyvax Ltd., a privately funded biotechnology company developing cancer vaccines and currently holds a position as Research Director.
Professor Dalgleish currently sits on 8 editorial boards; he has published over 300 peer-reviewed papers and authored or co-authored over 70 chapters in medical books. He is the co-editor of 5 medical books. He has been on numerous grant committees and is currently on the European Commission Cancer Board.
Professor Dalgleish’s career to date includes several key oncological discoveries that stemmed from an original interest in the pathogenesis of cancer. Some of these discoveries include: confirmed of the link between Hepatitis B (“HBV”) and liver cancer in native Australians, showing through the use of newly available sensitive assays that most instances were not due to alcohol as claimed before; co-discovered the CD4 receptor for ; published the first paper linking Slim Disease in East Africa with ; developed the theory of pathogenesis that only causes AIDS by immune activation and not by cytopathic killing; and investigated anti-idiotype and allogeneic based vaccines for and then applied the theory to cancer; pioneered melanoma vaccines in the U.K. (Megavax and CancerVax) and adapted this approach to prostate cancer. In Phase II active agent is 42% with near doubling of time to progression to disease, compared with matched cancers and the therapies (Journal Clinical Oncology 2005) and showed that even small volume colon cancer causes cell mediated immunosuppression, which is reverted following surgery and developed cancer arises due to chronic inflammation theory, thereby causing immunosuppression and angiogenesis and the ideal environment for stochastic changes to survival. Professor Dalgleish currently has an active interest in group optimizing dendritic cell treatment for cancer, both basic research and clinical groups and the identification of novel anti-inflammatory agent in vaccinated goat serum therapy is patent pending.
Dr. Fortunak received a PhD in organic chemistry from the University of Wisconsin, studying under Professor Barry Trost. After a postdoctoral stint at Cambridge University with Professor Ian Fleming, Dr. Fortunak spent 10 years at SmithKline Beecham (now part of GlaxoSmithKline) working in Process Chemistry and Drug Development. Dr. Fortunak worked for 8 years at Dupont Pharmaceuticals, rising to the level of Executive Director of Chemical Development. From 2000-2004 Dr. Fortunak served as the head of Global Chemical Development for Abbott Labs. While in Industry, Dr. Fortunak made significant contributions to 15 New Chemical Entities for the treatment of HIV/AIDS, malaria, cancer, and various cardiovascular and CNS indications. He also contributed to roughly 20 new generic drug launches. In 2004 Dr. Fortunak joined Howard University in Washington, DC with a joint appointment in Chemistry and Pharmaceutical Sciences. Dr. Fortunak consults in various advisory capacities for non-governmental organizations including the Clinton Foundation and the World Health Organization. He has worked with Indian drug companies on the approval of quality-assured medicines for supply to low-income countries through Donor Agencies including the Global Fund and PEPFAR. Dr. Fortunak teaches a four-course sequence in drug development for African Pharmaceutical Companies and National Drug Regulators at the St. Luke Foundation / Kilimanjaro School of Pharmacy in Moshi, Tanzania; to reduce the incidence of counterfeiting and encourage the availability of quality-assured medicines in sub-Saharan Africa. The SLF/KSP is short-listed as a Center of Excellence in drug manufacturing by the WHO ANDI organization. Dr. Fortunak is also a member of the Advisory Group on Funding Priorities for UNITAID. His research interests lie in Green Chemical Processing, new synthetic methods, and new applications of asymmetric synthesis. Dr. Joseph M. Fortunak, PHD holds a position, is an Associate Professor of Chemistry with a joint appointment in Pharmaceutical Sciences at Howard University in addition to consulting. Dr. Fortunak has over twenty years experience in the Pharmaceutical Industry, most recently as Director and Head of Global Process R&D at Abbott Laboratories Corporation where he managed 350+ scientists and technical experts.
Dr. Fortunak has been issued over 34 patents, launched 11 new molecular entities. During this history Dr. Fortunak led the API team for Losoxantrone (breast cancer) including all regulatory issues, marketing application and pre-approval inspections; led the API development team for Efavirenz, an inhibitor of HIV-1 reverse-transcriptase; invented commercial processes for the malaria drug Halofantrine and Ropinerole, a selective dopamine D3 antagonist for the treatment of Parkinson's disease; invented the commercial process for Topotecan, an inhibitor of Topoisomerase I for the treatment of breast, ovarian and small cell lung carcinomas and invented the API process for Eprosartan, an inhibitor of Angiotensin II for the treatment of hypertension and congestive heart failure.
Dr. Fortunak has been involved in generics & companies in Africa, India, China & Brazil, including the operation of two Chemical Pilot Plants, one for kilolab and a potent drug facility for R&D, and 3rd party manufacturing following cGMPs. Dr. Fortunak acts as a consultant for large NGOs providing essential medicines to developing nations. In addition he provides relevant and consulting services to the following: William J. Clinton Foundation HIV/AIDS Initiative I am a consultant for the Clinton Foundation’s HIV/AIDS Initiative (CHAI) and the World Health Organization; advising these organizations on pricing and production of antiretroviral drugs (ARVs) as well as advising generic manufacturers of ARVs on the requirements for Current Good Manufacturing Practice (cGMPs), general strategies for process development and route discovery for the production of Active Pharmaceutical Ingredients (APIs). National Academy of Sciences, Board on Chemical Sciences and Technology; Adjunct Professor University of Alabama, Green Chemistry Manufacturing Institute; Scientific Advisory Board LaGray Foundation for Drug Discovery and Development for Neglected Populations; Nigerian Institute of Pharmaceutical R&D (NIPRD) Developed and taught the first training course delivered in the West African Economic; Community (ECOWAS) on cGMP production of Active Pharmaceutical Ingredients (APIs) and finished dosage forms, July 11 – 16, 2005. Presently collaborating with NIPRD to develop a budget for construction of a cGMP facility to prepare APIs for antimalarial drugs and on Green Chemistry for manufacturing purposes.